News | October 08, 2024
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
CSPC will receive an upfront payment of $100 million from AstraZeneca
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Subscribe To Our Newsletter & Stay Updated
